ClinicaliQ Trial Snapshot
- Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer — Active Not Recruiting • Phase I / Phase II • Oncology • NCT05367440.
- Trial testing whether combining AZD5305 with hormone therapies is safe and effective for advanced prostate cancer.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of AZD5305 when given in combination with new hormonal agents (NHAs) in patients with Metastatic Prostate Cancer. Conditions: Metastatic Prostate Cancer Interventions: AZD5305, Enzalutamide, Abiraterone Acetate, Darolutamide, Apalutamide Lead Sponsor: AstraZeneca Planned Enrollment: 174 participants